文献速递乳腺癌

曲妥珠单抗+帕妥珠单抗联合或不联合节拍化疗治疗老年HER2阳性转移性乳腺癌:EORTC 75111-10114开放标签随机2期试验

Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
PubMed 文献 · Lancet Oncol · 2018-02-09

该多中心开放标签随机2期试验纳入80例≥70岁或≥60岁伴功能受限的HER2阳性转移性乳腺癌患者,随机接受曲妥珠单抗+帕妥珠单抗或联合节拍口服环磷酰胺。

要点

  • 联合组3-4级血栓栓塞事件4例(10%),双靶组0例。

核心结论

  • 在老年及虚弱HER2阳性转移性乳腺癌患者中,双靶联合节拍口服环磷酰胺较双靶单用延长中位PFS 7个月,安全性可接受。
  • 该方案序贯T-DM1可能延迟或替代紫杉类化疗需求。

研究设计与样本

  • 多中心、开放标签、随机2期试验,纳入欧洲8国30中心80例患者。
  • 患者为组织学证实HER2阳性转移性乳腺癌,转移阶段未接受化疗,年龄≥70岁或≥60岁伴方案定义的功能受限,ECOG 0-3,预期生存>12周。
  • 随机1:1接受节拍口服环磷酰胺50mg/日+曲妥珠单抗+帕妥珠单抗,或曲妥珠单抗+帕妥珠单抗 alone。
  • 曲妥珠单抗负荷8mg/kg后6mg/kg每3周;帕妥珠单抗负荷840mg后420mg每3周。
  • 主要终点为研究者评估的6个月PFS(RECIST 1.1),探索10%或以上差异。

主要发现

  • 80例患者随机,双靶组39例,联合组41例;56例(70%)G8评分≤14提示潜在虚弱。
  • 最常见3-4级不良事件:高血压双靶组6例(15%)vs联合组5例(12%),腹泻4例(10%)vs5例(12%),呼吸困难2例(5%)vs4例(10%),乏力3例(8%)vs2例(5%),疼痛2例(5%)vs2例(5%),血栓栓塞事件0例(0%)vs4例(10%)。
  • 双靶组4例无进展死亡(心脏骤停、腹膜感染、呼吸衰竭、不明原因猝死各1例),联合组1例死于心力衰竭。

关键数值与推荐

  • 联合组血栓栓塞事件4例(10%),双靶组0例。

临床怎么用

  • 对于老年或虚弱的HER2阳性转移性乳腺癌患者,可考虑双靶联合节拍口服环磷酰胺以提高PFS。
  • 疾病进展后可序贯T-DM1,可能延迟或避免紫杉类化疗。
  • 需关注联合组血栓栓塞事件及两组心脏毒性。

局限性

  • 2期试验样本量小(80例),主要终点未达统计学显著。
  • 开放标签设计,研究者评估PFS可能存在偏倚。
  • 结果需更大规模3期试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the high incidence of metastatic breast cancer and its related mortality in the elderly population, our knowledge about optimal treatment for older patients with cancer is far from adequate. We aimed to evaluate the efficacy of dual anti-HER2 treatment with or without metronomic chemotherapy in older patients with HER2-positive metastatic breast cancer. METHODS: We did a multicentre, open-label, randomised, phase 2 trial in 30 centres from eight countries in Europe, in patients with histologically proven, HER2-positive metastatic breast cancer, without previous chemotherapy for metastatic disease, who were 70 years or older, or 60 years or older with confirmed functional restrictions defined by protocol, and had a life expectancy of more than 12 weeks and a performance status according to WHO scale of 0-3. Eligible patients were randomly assigned (1:1) by an online randomisation system based on the minimisation method to receive metronomic oral cyclophosphamide 50 mg per day plus trastuzumab and pertuzumab, or trastuzumab and pertuzumab alone. Trastuzumab was given intravenously with a loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks. Pertuzumab was given intravenously with a loading dose of 840 mg, followed by 420 mg every 3 weeks. Patients were stratified by hormone receptor positivity, previous HER2 treatment, and baseline geriatric screening. The primary endpoint was investigator-assessed progression-free survival at 6 months as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. A difference of 10% or greater between the two groups was sought. Efficacy analyses were by intention to treat; safety was assessed in all patients who received at least one dose of study treatment. In case of progression, all patients were offered trastuzumab emtansine. This trial is registered with ClinicalTrials.gov, number NCT01597414, and is completed. FINDINGS: Between July 2, 2013, and May 10, 2016, 80 patients, of whom 56 (70%) had a potential frailty profile according to the geriatric screening G8 score (≤14), were randomly assigned to receive trastuzumab and pertuzumab (n=39) or trastuzumab and pertuzumab plus metronomic oral cyclophosphamide (n=41). Estimated progression-free survival at 6 months was 46·2% (95% CI 30·2-60·7) with trastuzumab and pertuzumab versus 73·4% (56·6-84·6) with trastuzumab and pertuzumab plus metronomic oral cyclophosphamide (hazard ratio [HR] 0·65 [95% CI 0·37-1·12], p=0·12). At a median follow-up of 20·7 months (IQR 12·5-30·4), the median progression-free survival was 5·6 months (95% CI 3·6-16·8) with trastuzumab and pertuzumab versus 12·7 months (6·7-24·8) with the addition of metronomic oral cyclophosphamide. The most frequent grade 3-4 adverse events were hypertension (in six [15%] of 39 patients in the trastuzumab and pertuzumab group vs five [12%] of 41 in the trastuzumab and pertuzumab plus metronomic oral cyclophosphamide group), diarrhoea (four [10%] vs five [12%]), dyspnoea (two [5%] vs four [10%]), fatigue (three [8%] vs two [5%]), pain (two [5%] vs two [5%]), and a thromboembolic event (0 [0%] vs four [10%]). Severe cardiac toxicities were occasionally observed in both groups. In the trastuzumab and pertuzumab group four patients died without progression, due to cardiac arrest during treatment (n=1), peritoneal infection (n=1), respiratory failure (n=1), and sudden death without a specified cause (n=1). In the trastuzumab and pertuzumab plus metronomic oral cyclophosphamide group, one patient died from heart failure. INTERPRETATION: Addition of metronomic oral cyclophosphamide to trastuzumab plus pertuzumab in older and frail patients with HER2-positive metastatic breast cancer increased median progression-free survival by 7 months compared with dual HER2 blockade alone, with an acceptable safety profile. Trastuzumab and pertuzumab plus metronomic oral cyclophosphamide, followed by trastuzumab emtansine after disease progression, might delay or supersede the need for taxane chemotherapy in this population. FUNDING: F Hoffmann-La Roche.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Wildiers H, Tryfonidis K, Dal Lago L, et al. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018. PMID: 29433963. doi:10.1016/S1470-2045(18)30083-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。